Drugs / F182112
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07816341 | Oct 2026 → Dec 2027 expected | autoimmune hemolytic anemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07829614 | Oct 2025 → Dec 2027 expected | systemic lupus erythematosus | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 1 | NCT04984434 | Jul 2021 → Jul 2023 | belinostat toxicity or dose selection | Shandong New Time Pharmaceutical Co., LTD | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07828522 | Oct 2026 → Oct 2027 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07312188 | Jul 2025 → May 2028 expected | refractory plasma cell neoplasm | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07579234 | Jan 2026 → Jan 2029 expected | refractory plasma cell neoplasm | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F182112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07312188 ↗ |
| Action | Deplete | “F182112 can effectively deplete BCMA-expressing B cells and plasma cells in vivo” NCT07816341 ↗ |
| Modality | Monoclonal antibody | “bispecific antibody” NCT07829614 ↗ |
| Route | Intravenous | “when infused intravenously (IV)” NCT04984434 ↗ |